Multimodal engineering of extracellular vesicles for efficient intracellular protein delivery
Xiuming Liang,Dhanu Gupta,Junhua Xie,Elien Van Wonterghem,Lien Van Hoecke,Justin Hean,Zheyu Niu,Oscar P. B. Wiklander,Wenyi Zheng,Rim Jawad Wiklander,Rui He,Doste R. Mamand,Jeremy Bost,Guannan Zhou,Houze Zhou,Samantha Roudi,Antje M. Zickler,André Görgens,Daniel W. Hagey,Olivier G. de Jong,Aileen Geobee Uy,Yuanyuan Zong,Imre Mäger,Carla Martin Perez,Thomas C. Roberts,Pieter Vader,Antonin de Fougerolles,Matthew J. A. Wood,Roosmarijn E. Vandenbroucke,Joel Z. Nordin,Samir EL Andaloussi
DOI: https://doi.org/10.1101/2023.04.30.535834
2024-04-22
Abstract:Extracellular vesicles (EVs) are promising tools to transfer macromolecular therapeutic molecules to recipient cells, however, efficient functional intracellular protein delivery by EVs remains challenging. Here, we have developed novel and versatile systems that leverage selected molecular tools to engineer EVs for robust cytosolic protein delivery both and . These systems, termed VSV-G plus EV-sorting Domain-Intein-Cargo (VEDIC) and VSV-G-Foldon-Intein-Cargo (VFIC), exploit an engineered mini-intein (intein) protein with self-cleavage activity to link cargo to an EV-sorting domain and release it from the EV membrane inside the EV lumen. In addition, we utilize the fusogenic protein VSV-G to facilitate endosomal escape and cargo release from the endosomal system to the cytosol of recipient cells. Importantly, we demonstrate that the combination of the self-cleavage intein, fusogenic protein and EV-sorting domain are indispensable for efficient functional intracellular delivery of cargo proteins by engineered EVs. As such, nearly 100% recombination and close to 80% genome editing efficiency in reporter cells were observed by EV-transferred Cre recombinase and Cas9/sgRNA RNPs, respectively. Moreover, EV-mediated Cre delivery by VEDIC or VFIC engineered EVs resulted in significant recombination in Cre-LoxP R26-LSL-tdTomato reporter mice following both local and systemic injections. Finally, we applied these systems for improved treatment of LPS-induced systemic inflammation by delivering a super-repressor of NF-ĸB activity. Altogether, this study describes a platform by which EVs can be utilized as a vehicle for the efficient intracellular delivery of macromolecular therapeutics for treatments of disease.
Bioengineering